BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35912248)

  • 1. Radiomic Signatures for Predicting
    Zheng L; Xie H; Luo X; Yang Y; Zhang Y; Li Y; Yin S; Li H; Xie C
    Front Oncol; 2022; 12():931812. PubMed ID: 35912248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics signature of brain metastasis: prediction of EGFR mutation status.
    Wang G; Wang B; Wang Z; Li W; Xiu J; Liu Z; Han M
    Eur Radiol; 2021 Jul; 31(7):4538-4547. PubMed ID: 33439315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiomic Signatures for Predicting Receptor Status in Breast Cancer Brain Metastases.
    Luo X; Xie H; Yang Y; Zhang C; Zhang Y; Li Y; Yang Q; Wang D; Luo Y; Mai Z; Xie C; Yin S
    Front Oncol; 2022; 12():878388. PubMed ID: 35734585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion tensor and postcontrast T1-weighted imaging radiomics to differentiate the epidermal growth factor receptor mutation status of brain metastases from non-small cell lung cancer.
    Park YW; An C; Lee J; Han K; Choi D; Ahn SS; Kim H; Ahn SJ; Chang JH; Kim SH; Lee SK
    Neuroradiology; 2021 Mar; 63(3):343-352. PubMed ID: 32827069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR-based radiomics predictive modelling of EGFR mutation and HER2 overexpression in metastatic brain adenocarcinoma: a two-centre study.
    Li Y; Jin Y; Wang Y; Liu W; Jia W; Wang J
    Cancer Imaging; 2024 May; 24(1):65. PubMed ID: 38773634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of radiomics model based on multi-parametric magnetic resonance imaging in predicting epidermal growth factor receptor mutation status in patients with lung adenocarcinoma.
    Wang Y; Wan Q; Xia X; Hu J; Liao Y; Wang P; Peng Y; Liu H; Li X
    J Thorac Dis; 2021 Jun; 13(6):3497-3508. PubMed ID: 34277045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric MRI-Based Radiomics Approaches for Preoperative Prediction of EGFR Mutation Status in Spinal Bone Metastases in Patients with Lung Adenocarcinoma.
    Jiang X; Ren M; Shuang X; Yang H; Shi D; Lai Q; Dong Y
    J Magn Reson Imaging; 2021 Aug; 54(2):497-507. PubMed ID: 33638577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis.
    Li Y; Lv X; Wang B; Xu Z; Wang Y; Gao S; Hou D
    Eur J Radiol; 2022 Oct; 155():110499. PubMed ID: 36049410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
    Li Y; Lv X; Chen C; Yu R; Wang B; Wang D; Hou D
    Eur Radiol Exp; 2024 Jan; 8(1):2. PubMed ID: 38169047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Radiomics to Differentiate Brain Metastases From Lung Cancer Versus Breast Cancer, Including Predicting Epidermal Growth Factor Receptor and human Epidermal Growth Factor Receptor 2 Status.
    Shi J; Chen H; Wang X; Cao R; Chen Y; Cheng Y; Pang Z; Huang C
    J Comput Assist Tomogr; 2023 Nov-Dec 01; 47(6):924-933. PubMed ID: 37948368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.
    Chen BT; Jin T; Ye N; Mambetsariev I; Daniel E; Wang T; Wong CW; Rockne RC; Colen R; Holodny AI; Sampath S; Salgia R
    Magn Reson Imaging; 2020 Jun; 69():49-56. PubMed ID: 32179095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multisequence MRI-based radiomics signature as potential biomarkers for differentiating KRAS mutations in non-small cell lung cancer with brain metastases.
    Lv X; Li Y; Wang B; Wang Y; Xu Z; Hou D
    Eur J Radiol Open; 2024 Jun; 12():100548. PubMed ID: 38298532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting EGFR mutation subtypes in lung adenocarcinoma using
    Liu Q; Sun D; Li N; Kim J; Feng D; Huang G; Wang L; Song S
    Transl Lung Cancer Res; 2020 Jun; 9(3):549-562. PubMed ID: 32676319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.
    Li Y; Lv X; Wang B; Xu Z; Wang Y; Sun M; Hou D
    Acad Radiol; 2023 Sep; 30(9):1887-1895. PubMed ID: 36586758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma.
    Lu X; Li M; Zhang H; Hua S; Meng F; Yang H; Li X; Cao D
    Phys Med Biol; 2020 Mar; 65(5):055012. PubMed ID: 31978901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI-based radiomics analysis for predicting the EGFR mutation based on thoracic spinal metastases in lung adenocarcinoma patients.
    Ren M; Yang H; Lai Q; Shi D; Liu G; Shuang X; Su J; Xie L; Dong Y; Jiang X
    Med Phys; 2021 Sep; 48(9):5142-5151. PubMed ID: 34318502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics of Spinal Metastases Originating From Primary Nonsmall Cell Lung Cancer or Breast Cancer and Ability to Predict Epidermal Growth Factor Receptor Mutation/Ki-67 Levels.
    Niu S; Zhang H; Wang X; Jiang W
    J Comput Assist Tomogr; 2023 Jul-Aug 01; 47(4):643-649. PubMed ID: 37380152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-enhanced T1-weighted image radiomics of brain metastases may predict EGFR mutation status in primary lung cancer.
    Ahn SJ; Kwon H; Yang JJ; Park M; Cha YJ; Suh SH; Lee JM
    Sci Rep; 2020 Jun; 10(1):8905. PubMed ID: 32483122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of pre-therapy
    Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
    Yang X; Fang C; Li C; Gong M; Yi X; Lin H; Li K; Yu X
    Front Oncol; 2022; 12():904983. PubMed ID: 35875167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.